Intellia Therapeutics, Inc. (NTLA) Stock Analysis
A live, multi-source view of Intellia Therapeutics, Inc. (NTLA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd.
Sector: Healthcare · Industry: Biotechnology · United States · 377 employees · intelliatx.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Intellia Therapeutics, Inc. (NTLA) had a market capitalization of $1.79B (forward -4.9) and a beta of 1.82; the shares traded in a 52-week range of $7.95 – $28.25 (7.6% over the year).
- Market cap
- $1.79B
- Enterprise value
- $1.42B
- Forward P/E
- -4.9
- Price / book
- 2.45
- EPS (trailing)
- $-3.34
- EPS (forward)
- $-2.60
- Payout ratio
- 0.0%
- 52-week range
- $7.95 – $28.25
- 52-week change
- 7.6%
- Beta
- 1.82
- Average volume
- 4.6M
- Shares outstanding
- 140.1M
- Short % of float
- 40.35%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Intellia Therapeutics, Inc. (NTLA) last closed at $11.93 (the last completed close before that scan).
Technicals at the scan: RSI 43 (neutral territory), price -5.2% versus its 20-day average, 20-day versus 50-day average spread -0.5%, MACD histogram -0.06.
Sentiment inputs: 93% of recent Finnhub-scored headlines read bullish; StockTwits 79% bullish; analyst consensus score 59/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of NTLA; corporate insiders filed 0 buys and 3 sells (2 distinct filers, latest disclosure 2026-08-24). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: John M. Leonard (0B/2S), Edward J. Dulac III (0B/1S). Who is trading what
RapidTradeView pick record
NTLA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Intellia Therapeutics, Inc. (NTLA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell NTLA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.